Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Despite improved understanding of the pathobiology of pulmonary arterial hypertension
(PAH) and the availability of guidelines for risk stratification, PAH continues to
be misidentified and underdiagnosed. Furthermore, new treatment paradigms have emerged
as the number and types of pharmacotherapy for PAH continue to increase. Indeed, myriad
options for monotherapy, drug combinations, and sequential treatment can be used to
tailor therapy for patients with PAH and improve outcomes. For clinicians, these options
can increase the likelihood of confusion and medical errors, especially during patient
This activity will provide nurses and pharmacists with an improved foundational knowledge of PAH, including disease subcategories, diagnosis, treatment guidelines, approved therapies, and disease monitoring recommendations. Discussions will emphasize collaborative care and the importance of interprofessional communication, particularly between outpatient and inpatient teams. Strategies for effective patient-caregiver communication will also be discussed and illustrated through the use of interactive case studies.
The target audience for this activity includes pharmacists and nurses in health-system settings. After completing the activity, participants should be able to:
James C. Coons, PharmD, FCCP, BCPS-AQ Cardiology
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Jennifer Kliner, MSN, ACNP-BC
Clinical Project Director
Advanced Heart Failure and Pulmonary Hypertension Programs
Program Coordinator, Comprehensive Pulmonary Hypertension Program
University of Pittsburgh Medical Center Heart and Vascular Institute
Release Date: 2-8-2018
Expiration Date: 2-8-2019
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-18-017-H01-P has been assigned to this home study knowledge-based activity (initial release date 2-08-18). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education,
Inc. This activity provides 1.5 contact hours of nurse CE credit.
Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Coons is a
Consultant for Medicure and an Investigator for United Therapeutics. Ms. Kliner has
no relevant commercial or financial relationships to disclose. A portion of grant
funds received by ProCE from Actelion Pharmaceuticals US, Inc. and Bayer HealthCare
Pharmaceuticals Inc. will be used to compensate the faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is provided by ProCE, Inc. and is supported by an educational grant from Actelion Pharmaceuticals US, Inc. and Bayer HealthCare Pharmaceuticals Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.